NKX6-1 and diabetes mellitus: For example, in the db/db mouse model of diabetes, treatment with the SGLT2 inhibitor, Luseogliflozin, which does not act directly on beta cells, restored insulin secretion by reducing oxidative stress, which was correlated with increased expression of NKX6.1 (38).